Skip to content
Menu

Haemonetics Corporation HAE

Full chart Compare
Set alert

Price alert · HAE

All alert types
120.16 USD -0.21 (-0.17%)

Regular-session close

120.16 0.00 0.00%

After hours · Nov 20, 5:31 PM ET

119.68 Day range 122.00
52.24 52-week range 127.42
YTD
+49.92%
1 year
+59.96%

5D -3.02 (-2.45%)

120122124MonTueWedThuFri120.16
Market cap
5.47B
Revenue (ttm)
1.38B
Profit margin
7.52%
EPS (ttm)
2.26
Shares out
45.54M
P/E ratio
53.17
Forward P/E
19.16
YTD return
+49.92%
1-year return
+59.96%
50-day average
114.82
Volume
382.96K
Avg volume
662.81K
Open
120.37
Previous close
120.37
Day's range
119.68 – 122.00
52-week range
52.24 – 127.42
Beta
0.59
Analysts
Buy
Price target
147.18 (+22.5%)
Earnings date
Feb 4, 2027

Key statistics

200-day average
82.37
Enterprise value
6.34B
PEG ratio
1.92
Price / sales
3.96
Price / book
6.09
Revenue growth
9.30%
Free cash flow
297.44M
Total cash
262.91M
Total debt
1.12B
Return on equity
11.89%
Short % of float
9.25%

Fundamental scorecard

11 of 25 checks passed on HAE’s reported financials

ValueGrowthProfitabilityHealthDividend

11of 25 checks passed

  • Value 1 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 26, 2026.

Financials — quick view

All financials
HAE Revenue — quarterly 357.76M
HAE Net income — quarterly 46.30M
HAE EPS — quarterly 1.02

Earnings

HAE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 4, 2027Dec 26, 20261.26———
Nov 5, 2026Sep 26, 20261.291.35+0.06+4.65%
Aug 6, 2026Jun 27, 20261.081.14+0.06+5.56%
May 7, 2026Mar 28, 20261.281.29+0.01+0.78%
Feb 5, 2026Dec 27, 20251.271.31+0.04+3.15%
Nov 6, 2025Sep 27, 20251.121.27+0.15+13.39%

Upgrades / downgrades

HAE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 16, 2026CitizensmainMarket OutperformMarket Outperform
Nov 13, 2026Jefferiesinit—Buy
Nov 6, 2026CitigroupmainBuyBuy
Nov 6, 2026Barrington ResearchmainOutperformOutperform
Nov 5, 2026BTIGmainBuyBuy
Oct 9, 2026Barrington ResearchmainOutperformOutperform

About Haemonetics Corporation

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on HAE — it syncs with the Stock Master app.

Insider holders

HAE insider holders
InsiderRelationLatest transactionDateShares held
ABERNATHY ROBERT EDirectorStock Award(Grant)Jul 23, 202627,519
BASIL MICHELLE LGeneral CounselStock Award(Grant)May 14, 202668,829
DARECCA JAMESChief Financial OfficerStock Award(Grant)May 14, 202654,444
DOCKENDORFF CHARLES JDirectorStock Award(Grant)Jul 23, 202525,041
GALVIN ROYOfficerStock Award(Grant)May 14, 202639,882
KROLL MARK WDirectorStock Award(Grant)Jul 23, 202627,295

Institution ownership

HAE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.13.07%5,953,537715.02MSep 29, 2026
Neuberger Berman Group, LLC7.65%3,481,774418.16MSep 29, 2026
Vanguard Portfolio Management LLC5.49%2,501,221300.40MSep 29, 2026
Ariel Investments, LLC4.77%2,173,575261.05MSep 29, 2026
Vanguard Capital Management LLC4.49%2,045,810245.70MSep 29, 2026
AQR Capital Management, LLC4.00%1,822,616218.90MSep 29, 2026

Fund ownership

HAE fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,621,301194.72MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%1,441,654173.14MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.62%1,194,166143.42MSep 29, 2026
NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund2.59%1,179,168141.62MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%1,041,356125.07MJun 29, 2026
Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com1.35%614,82473.84MJun 29, 2026